Belite Bio is a clinical-stage biopharmaceutical drug development company advancing novel therapeutics for degenerative retinal diseases with significant unmet medical need, including geographic atrophy in advanced dry age-related macular degeneration and autosomal recessive Stargardt disease type 1.
The company's pipeline is built on its retinol binding protein 4 (RBP4) intellectual property portfolio. Its lead candidate, tinlarebant (LBS-008), is an oral therapy designed to reduce the accumulation of toxic vitamin A byproducts in the retina, acting on the upstream driver of retinal degeneration rather than its downstream damage. Belite Bio also develops LBS-009, a preclinical anti-RBP4 oral therapy aimed at liver disease and type 2 diabetes, extending the RBP4 approach beyond the eye.
Belite Bio is a clinical-stage biopharmaceutical company developing oral therapies targeting retinol binding protein 4 for degenerative retinal diseases.